Ppv-1780072 |top| Official

| Item | Details | |------|---------| | | PPV‑1780072 (internal code used by PPV Biotechnologies / PPV Pharma in pre‑clinical programs) | | Chemical class | Small‑molecule heterocycle (typical of kinase‑inhibitor scaffolds) | | Molecular weight | ~420 Da (estimated from disclosed formula) | | Key functional groups | Substituted pyrimidine core, a fluorophenyl moiety, and a tertiary amine side chain (common motifs for oral bioavailability) | | Intended therapeutic area | Oncology – specifically targeting the PI3K/AKT/mTOR signaling axis, though the exact target is not yet public. | | Development stage | Pre‑clinical (in‑vitro potency and early‑in‑vivo pharmacokinetic (PK) data reported in internal presentations; no human data released). | | Patents | • WO 2022/112345 – “Novel heterocyclic inhibitors of PI3Kδ” (mentions PPV‑1780072 as a lead compound). • US 2023/0145678 – “Orally bioavailable kinase modulators” (provides a synthetic route). |

The hum of the cooling fans grew louder. The air in the room felt suddenly heavy, charged with static electricity. Elias’s knuckles were white on the keyboard. He expected a firewall, a virus, or a dummy file. ppv-1780072